Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Cash from Financing Activities (2020 - 2025)

Maxcyte (MXCT) has disclosed Cash from Financing Activities for 6 consecutive years, with $14000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 93.86% to $14000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $963000.0, a 54.94% decrease, with the full-year FY2024 number at $2.1 million, down 4.06% from a year prior.
  • Cash from Financing Activities was $14000.0 for Q3 2025 at Maxcyte, down from $154000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $184.6 million in Q3 2021 to a low of $14000.0 in Q3 2025.
  • A 5-year average of $12.8 million and a median of $444400.0 in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 70325.91% in 2021, then tumbled 99.76% in 2022.
  • Maxcyte's Cash from Financing Activities stood at $1.2 million in 2021, then rose by 1.52% to $1.2 million in 2022, then crashed by 59.77% to $493000.0 in 2023, then decreased by 16.43% to $412000.0 in 2024, then tumbled by 96.6% to $14000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cash from Financing Activities are $14000.0 (Q3 2025), $154000.0 (Q2 2025), and $383000.0 (Q1 2025).